title: CD109 expression in basal-like breast carcinoma.
abstract: Breast cancer can be classified into several subtypes based on gene expression profiling. Basal-like breast carcinoma (BLC) has a triple negative phenotype, that is, the subtype lacks the estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2). It has been recently reported that CD109, a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, is a new breast myoepithelial marker. In the present study CD109 expression was investigated in invasive ductal carcinomas (IDC) of the breast on immunohistochemistry. Eighty-eight formalin-fixed, paraffin-embedded breast carcinoma sections were immunostained with anti-CD109, anti-cytokeratin 5/6 (CK5/6), anti-calponin, anti-vimentin and anti-p63 antibodies. CD109 expression was detected in 18 of 30 basal-like breast carcinomas (BLC) but not in other types of 53 IDC (non-BLC) that were positive for ER, PgR and/or HER2. The percentage of CD109-positive tissues (60%) in BLC was similar to that of CK5/6 (63%) and higher than that of other myoepithelial markers including p63 (23%), calponin (33%) and vimentin (33%). Statistical analysis indicated that the CD109-positive group in BLC, but not the CK5/6-positive group in BLC, was associated with reduced fat invasion (P < 0.05). These findings indicate that CD109 is a useful diagnostic marker for BLC and that CD109 expression may affect biological properties of cancer cells.
authors.affiliation: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Suzuko
authors.initials: S
authors.lastname: Moritani
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Murakumo
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sato
authors.forename: Sumitaka
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Chikage
authors.initials: C
authors.lastname: Suzuki
authors.forename: Shinji
authors.initials: S
authors.lastname: Mii
authors.forename: Mayumi
authors.initials: M
authors.lastname: Jijiwa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Enomoto
authors.forename: Naoya
authors.initials: N
authors.lastname: Asai
authors.forename: Shu
authors.initials: S
authors.lastname: Ichihara
authors.forename: Masahide
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001940:Breast / Q000378:metabolism / Q000473:pathology*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D058851:GPI-Linked Proteins; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C120523:CD109 protein, human; D058851:GPI-Linked Proteins; D009363:Neoplasm Proteins